Out-of-pocket prescription drug costs for adults with cardiovascular risk factors under Amazon's direct-to-consumer pharmacy service
- 15 February 2024
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 271, 20-27
Abstract
No abstract availableKeywords
Funding Information
- National Heart Lung and Blood Institute
This publication has 18 references indexed in Scilit:
- Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction ActJACC, 2023
- Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022JAMA Health Forum, 2023
- Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: “Real‐world” evidenceClinical Cardiology, 2022
- Financial Burdens of Out-of-Pocket Prescription Drug Expenditures under High-Deductible Health PlansJournal of General Internal Medicine, 2020
- Association of Out-of-Pocket Annual Health Expenditures With Financial Hardship in Low-Income Adults With Atherosclerotic Cardiovascular Disease in the United StatesJAMA Cardiology, 2018
- Frequency and Magnitude of Co-payments Exceeding Prescription Drug CostsJAMA, 2018
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor TherapyJAMA Cardiology, 2017
- The High Cost of Prescription Drugs in the United StatesJAMA, 2016
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialThe Lancet, 2003